Drugs and Money: Managing the Drug Trade and Crime Money in Europe: Organizational Crime
Autor Michael Levi, Petrus C. van Duyneen Limba Engleză Paperback – 11 aug 2005
In this intriguing book, Petrus C. van Duyne and Michael Levi expose an ever-unfolding series of problems:
- the proliferation of mind-influencing substances
- the complications of international drug regulation
- the interaction between markets and economic actors, with the consequent amassing of huge amounts of crime-money.
Toate formatele și edițiile | Preț | Express |
---|---|---|
Paperback (1) | 477.62 lei 6-8 săpt. | |
Taylor & Francis – 11 aug 2005 | 477.62 lei 6-8 săpt. | |
Hardback (1) | 1300.08 lei 6-8 săpt. | |
Taylor & Francis – 23 dec 2004 | 1300.08 lei 6-8 săpt. |
Preț: 477.62 lei
Nou
Puncte Express: 716
Preț estimativ în valută:
91.44€ • 95.04$ • 75.81£
91.44€ • 95.04$ • 75.81£
Carte tipărită la comandă
Livrare economică 05-19 februarie 25
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9780415354752
ISBN-10: 0415354757
Pagini: 224
Ilustrații: 7 tables and 7 line drawings
Dimensiuni: 156 x 234 x 12 mm
Greutate: 0.41 kg
Ediția:1
Editura: Taylor & Francis
Colecția Routledge
Seria Organizational Crime
Locul publicării:Oxford, United Kingdom
ISBN-10: 0415354757
Pagini: 224
Ilustrații: 7 tables and 7 line drawings
Dimensiuni: 156 x 234 x 12 mm
Greutate: 0.41 kg
Ediția:1
Editura: Taylor & Francis
Colecția Routledge
Seria Organizational Crime
Locul publicării:Oxford, United Kingdom
Public țintă
Postgraduate and UndergraduateCuprins
1. The Mind, Drugs and the Policy of Fear 2. Enfolding of Illegal Drugs Markets in Europe 3. Commerce, Constraints and Enterprise Features 4. Drug Markets in Action 5. The Volume of Drug-Money and Money Management 6. The Craft of Laundering and the Counter Reaction 7. Haunted: By Drugs or Money?
Notă biografică
Michael Levi, Petrus C. van Duyne
Descriere
In this intriguing book, Petrus C. van Duyne and Michael Levi introduce the reader to an ever-unfolding series of problems, from mind-influencing substances to the complications of international drug regulation and the interaction between markets